ArticleJournal of transplantation2017

The CECARI Study: Everolimus (Certican®) Initiation and Calcineurin Inhibitor Withdrawal in Maintenance Heart Transplant Recipients with Renal Insufficiency: A Multicenter, Randomized Trial.

Jan Van Keer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.